3-MeO-PCP: Difference between revisions

From Drugwiki

Jump to: navigation, search
Newer edit →
 
m Undo revision 166801 by Blackhole (talk)
Line 1: Line 1:
[[File:3meopcp.jpg|right|3-MeO-PCP in a pill form]]
{{headerpanel|{{Warning/3-MeO-PCP}}}}
{{Distinguish|4-MeO-PCP}}
{{SummarySheet}}
{{SubstanceBox/3-MeO-PCP}}


'''3-Methoxyphencyclidine''' (3-MeO-PCP) is a dissociative anesthetic drug that is sold online as a research chemical.
'''3-Methoxyphencyclidine''' (also known as '''3-MeO-PCP''') is a lesser-known novel [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class. 3-MeO-PCP is a derivative of [[phencyclidine]] ('''PCP''') and is chemically related to substances like [[methoxetamine]] and [[3-MeO-PCE]]. It produces its effects by blocking [[NMDA receptor|NMDA receptors]] in the brain.  
The effects are often described as being more euphoric and mentally clearer than many related compounds.


== History ==
3-MeO-PCP was first synthesized in 1979 in an investigation of [[phencyclidine]] (PCP) derivatives. However, its activity in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle reported qualitative similarities to [[PCP]] along with comparable potency.<ref name="Morris2014">{{cite journal | vauthors=((Morris, H.)), ((Wallach, J.)) | journal=Drug Testing and Analysis | title=From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs: PCP to MXE | volume=6 | issue=7–8 | pages=614–632 | date= July 2014 | url=https://onlinelibrary.wiley.com/doi/10.1002/dta.1620 | issn=19427603 | doi=10.1002/dta.1620}}</ref> In 2009, it began to be discussed on online forums such as bluelight.ru and was made available for sale on the [[research chemicals]] market.<ref name="Morris2014" />


A 1965 article published by Maddox described the synthesis of 2-MeO-PCP and 4-MeO-PCP. Preparation of 3-MeO-PCP was described later in 1979 by Geneste et al.
Like other arylcyclohexylamines, 3-MeO-PCP induces a state referred to as "[[dissociatives#Subjective effects|dissociative anesthesia]]", although the extent to which this occurs is reported to be highly dose-dependent and variable in its effects. It is commonly taken [[orally]] and [[nasally]], although it may also be [[smoked]] and [[injected]]. It has been noted for its subtle come up and tendency to produce [[Delusions#Delusion of sobriety|delusions of sobriety]], which can lead to [[compulsive redosing]].


The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in man was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.
Very little data exists for the pharmacology, metabolism, and toxicity of 3-MeO-PCP. Due to its potent hallucinogenic effects and lack of research, it is strongly advised to use use [[harm reduction practices]] if using this substance.


== Dosage ==
==Chemistry==
3-Methoxyphencyclidine, or 3-MeO-PCP, is a synthetic dissociative of the arylcyclohexylamine class. 3-MeO-PCP contains cyclohexane, a six-member saturated ring, bonded to two additional rings at R<sub>1</sub>. One of these rings is a piperidine ring, a nitrogenous six member ring, bonded at its nitrogen group. The other ring is an aromatic phenyl ring, substituted at R<sub>3</sub> with a methoxy group.


3-MeO-PCP, like PCP is active in the single milligram range and therefor can be hard to accurately measure.
3-MeO-PCP is a [[PCP]] derivative and structurally analogous to [[4-MeO-PCP]].


'''Most if not all consumer-grade jewelry-scales advertised as working at the 0.001g (mg) range are not reliably accurate enough to measure quantities weighing less than around 15-25 mg depending on the model and calibration.
==Pharmacology==
With a drug as potent as 3-MeO-PCP a small discrepancy in measurement can make a world of difference in physical and mental response to the dose.
{{Further|NMDA receptor antagonist}}
It is for these reasons that it would be in one's best interest to use a [https://wiki.tripsit.me/wiki/Quick_Guide_to_Volumetric_Dosing volumetric dose measurement technique as outlined in this guide.]'''
3-MeO-PCP acts as an [[NMDA receptor antagonist]]. A specific subtype of glutamate receptor, NMDA (N-Methyl-D-Aspartate), modulates the transmission of electrical signals between neurons in the brain and spinal cord; for the signals to pass, the receptor must be open.  


{| class="wikitable"
Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually the equivalent of a "k-hole".


|+ Oral
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 42 nM for the sigma-1 receptor, 216 nM for the serotonin transporter (SERT), and 2960 nM with H1 receptor <ref>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984</ref> <ref name="&quot;AMCD&quot;">{{Citation | title=Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012 | url=https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012}}</ref> It binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP.<ref>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984</ref>  Like its sister compound PCP and unlike ketamine, 3-MeO-PCP shows a high affinity for inhibiting the relatively unstudied PCP2 glutamate receptor.{{Citation needed}}


|-
Although 3-MeO-PCP was once claimed to possess opioid or dopaminergic activity,<ref name="chemist">{{Citation | vauthors=((Morris, H.)) | year=2011 | title=Interview with a Ketamine Chemist | url=https://www.vice.com/en/article/ppzgk9/interview-with-ketamine-chemist-704-v18n2}}</ref> this supposition is contradicted by data showing 3-MeO-PCP to be a potent and selective ligand for the NMDA receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter.<ref name="AMCD2">{{cite journal | vauthors=((Roth, B. L.)), ((Gibbons, S.)), ((Arunotayanun, W.)), ((Huang, X.-P.)), ((Setola, V.)), ((Treble, R.)), ((Iversen, L.)) | journal=PLOS ONE | title=The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor | volume=8 | issue=3 | pages=e59334 | date=19 March 2013 | url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059334 | issn=1932-6203 | doi=10.1371/journal.pone.0059334}}</ref> 3-MeO-PCP was preceded by the less potent dissociative 4-MeO-PCP and first became available as a [[research chemical]] in 2011.<ref name="Morris2014" />


| Threshold || 1.5-3 mg
==Subjective effects==
3-MeO-PCP is commonly described as being more stimulating and less immobilizing than other [[dissociatives]] such as [[ketamine]] or [[MXE]].  


|-
At lower doses, it can induce sensory enhancements such as [[color enhancement]], [[acuity enhancement]], [[tactile enhancement]], [[auditory enhancement]] and [[bodily control enhancement]]. At medium to high doses it presents sensory suppressions such as [[tactile suppression]], [[motor control loss]], [[auditory suppression]] and [[acuity suppression]].


| Light || 3-5 mg
Based on a large amount of experience reports, it appears to be considerably more likely to induce [[mania]], [[delusions]], and [[psychosis]] than other dissociatives (possibly due to its unusually high potency, [[compulsive redosing|compulsivity]] and erratic dose response).
{{Preamble/SubjectiveEffects}}


|-
{{effects/base


| Common || 5-10 mg
|{{effects/physical|


|-
*'''[[Effect::Stimulation]]''' - 3-MeO-PCP is regarded to be noticeably stimulating in comparison to other dissociatives such as [[ketamine]], [[MXE]], or [[DCK]]. The stimulation it presents is described as clear and subtle.
*'''[[Effect::Spontaneous bodily sensations]]''' - The body high of 3-MeO-PCP can be described in terms of its style variations as a motionless, constant, sharp, all-encompassing, and euphoric activation of nerve endings across the body.
*'''[[Effect::Physical euphoria]]''' - 3-MeO-PCP has been reported to more readily induce euphoria than most other dissociatives, such as [[ketamine]] or [[diphenidine]], especially of the manic variant.
*'''[[Effect::Tactile enhancement]]''' or '''[[Effect::Tactile suppression]]''' - At lower dosages, this compound tends to induce tactile enhancements. At higher dosages, this enhancement shifts towards tactile suppressions and [[pain relief|anesthesia]].
*'''[[Effect::Pain relief]]''' - This substance produces distinct nerve-signal blocking anesthetic effects typically required in surgical settings, but only in the stronger to heavier dose ranges.
*'''[[Effect::Bodily control enhancement]]''' or '''[[Motor control loss]]''' - At lower dosages this compound typically induces enhancements in bodily control. At higher dosages, this enhancement shifts towards motor control loss.
*'''[[Effect::Spatial disorientation]]''' - In contrast to other dissociatives like ketamine, this effect is only prominent at high doses.
*'''[[Effect::Appetite suppression]]''' or '''[[Effect::Appetite enhancement]]''' - The appetite suppression present with 3-MeO-PCP can be considered to be less sharp than with substances such as [[Cocaine]] and [[Ketamine]].  Like ketamine, this is due to the disconnection of electrical signals at high doses.  Unlike ketamine, it is also possible to experience a noticeable appetite enhancement that is less prominent than its sister compound [[PCP]].
*'''[[Effect::Nausea suppression]]'''
*'''[[Effect::Restless legs]]'''
*'''[[Effect::Respiratory depression]]''' - This effect can be present at heavier dosage levels.{{citation needed}}
*'''[[Effect::Physical autonomy]]'''
*'''[[Effect::Olfactory hallucination]]'''
*'''[[Effect::Optical sliding]]'''
*'''[[Effect::Vibrating vision]]''' - At high doses, a person's eyeballs may begin to spontaneously wiggle back and forth in a rapid motion, causing the vision to become blurry and temporarily out of focus.<ref name="Berar et. al"/> This is a condition known as [http://en.wikipedia.org/wiki/Nystagmus nystagmus].
*'''[[Effect::Abnormal heartbeat]]'''
*'''[[Effect::Increased blood pressure]]''' - This effect grows more pronounced with increased dose.<ref name="Berar et. al">{{cite journal | vauthors=((Berar, A.)), ((Allain, J.-S.)), ((Allard, S.)), ((Lefevre, C.)), ((Baert, A.)), ((Morel, I.)), ((Bouvet, R.)), ((Gicquel, T.)) | journal=Medicine | title=Intoxication with 3-MeO-PCP alone: A case report and literature review | volume=98 | issue=52 | pages=e18295 | date= December 2019 | url=https://journals.lww.com/10.1097/MD.0000000000018295 | issn=0025-7974 | doi=10.1097/MD.0000000000018295}}</ref>
*'''[[Effect::Increased heart rate]]'''<ref name = "Berar et. al"/> - This effect has been reported as being more pronounced than other dissociatives, such as [[DCK]] or [[diphenidine]].
*'''[[Effect::Increased perspiration]]'''
*'''[[Effect::Dehydration]]'''
*'''[[Effect::Dizziness]]'''
*'''[[Effect::Difficulty urinating]]'''
*'''[[Effect::Seizure]]''' - The extent to which this effect can be produced is unknown but can likely happen in those predisposed to them, especially while in physically taxing conditions such as being dehydrated, fatigued or undernourished.


| Strong || 10-15 mg
}}
{{effects/visual|


|-  
*'''[[Effect::Visual acuity enhancement]]''' or '''[[Effect::Visual acuity suppression]]''' - While lower doses of this compound tend to produce mild visual acuity enhancements, this effect quickly disappears as one's general visual faculties become suppressed as the dose is increased.
*'''[[Effect::Double vision]]'''
*'''[[Effect::Frame rate suppression]]'''
*'''[[Effect::Pattern recognition suppression]]'''


| Heavy || 15-18 mg+
====Distortions====
*'''[[Effect::Perspective distortions]]'''
*'''[[Effect::Scenery slicing]]'''


|}
====Hallucinatory states====
*'''[[Effect::Internal hallucination]]''' (''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'')


{| class="wikitable"
}}
|{{effects/cognitive|


|+ Insufflated
*'''[[Effect::Anxiety suppression]]'''
*'''[[Effect::Disinhibition]]'''
*'''[[Effect::Cognitive euphoria]]'''
*'''[[Effect::Compulsive redosing]]''' - This effect is more prominent based on the route of administration used. For example, it is especially present when smoked or vaporized, due to the relative abruptness of the substance entering and leaving the bloodstream.
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Creativity enhancement]]'''
*'''[[Effect::Déjà vu]]'''
*'''[[Effect::Mania]]''' - This effect is reportedly more common on 3-MeO-PCP than most other dissociatives. It typically occurs during the offset of the experience, but can also occur during the onset and come up as well.
*'''[[Effect::Depersonalization]]''' & '''[[Effect::Derealization]]'''
*'''[[Effect::Psychosis]]''' - This effect has been reported to be more common on 3-MeO-PCP than most other dissociatives, such as [[MXE]] or [[ketamine]]. It typically occurs during the [[offset]] of the experience, but can also occur during the [[onset]] and come up as well.
*'''[[Effect::Delusion]]''' - Like psychosis, this effect is reportedly more common on 3-MeO-PCP than most other dissociatives.
*'''[[Effect::Dream potentiation]]'''
*'''[[Effect::Memory suppression]]'''
**'''[[Effect::Ego death]]'''
**'''[[Effect::Amnesia]]'''
*'''[[Effect::Immersion enhancement]]'''
*'''[[Effect::Increased music appreciation]]'''
*'''[[Effect::Time distortion]]'''
*'''[[Effect::Thought deceleration]]'''
*'''[[Effect::Increased libido]]''' - This is reported to be present at lower dosage ranges.


|-
====Suppressions====
*[[Effect::Addiction suppression]]


| Threshold || 1-2 mg
}}
{{effects/auditory|


|-
*'''[[Effect::Auditory enhancement]]''' - This effect is reported to only occur at lower doses.
*'''[[Effect::Auditory suppression]]'''
*'''[[Effect::Auditory distortion]]'''
*'''[[Effect::Auditory hallucination]]'''


| Light || 2-5 mg
}}
{{effects/disconnective|
*'''[[Effect::Tactile disconnection]]'''
*'''[[Effect::Visual disconnection]]''' - This eventually results in 3-MeO-PCP's equivalent of the "[https://en.wikipedia.org/wiki/K-hole k-hole]" or, more specifically, ''[[Visual disconnection#Holes, spaces and voids|holes, spaces and voids]]'' alongside of ''[[Visual disconnection#Structures|structures]]''.
*'''[[Effect::Consciousness disconnection]]'''


|-
}}
{{effects/transpersonal|


| Common || 5-8 mg
*'''[[Effect::Existential self-realization]]'''
}}
}}
===Experience reports===
Anecdotal reports which describe the effects of this compound within our [[experience index]] include:
{{#ask: [[Category:3-MeO-PCP]][[Category:Experience]]|format=ul|Columns=1}}
Additional experience reports can be found here:


|-
*[https://www.erowid.org/experiences/subs/exp_3MeOPCP.shtml Erowid Experience Vaults: 3-MeO-PCP]


| Strong || 8-12 mg
==Toxicity and harm potential==
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
The toxicity and long-term health effects of recreational 3-MeO-PCP use has not been studied in any scientific context and the exact [[Toxicity::toxic dosage is unknown]]. This is because 3-MeO-PCP has very short history of human usage.


|-
There is one death involving this substance recorded in the medical literature. In this case, the individual's cause of death was determined to be from a combination of 3-MeO-PCP, [[amphetamine]], and [[diphenhydramine]].<ref>{{cite journal | vauthors=((Bakota, E.)), ((Arndt, C.)), ((Romoser, A. A.)), ((Wilson, S. K.)) | journal=Journal of Analytical Toxicology | title=Fatal Intoxication Involving 3-MeO-PCP: A Case Report and Validated Method | volume=40 | issue=7 | pages=504–510 | date= September 2016 | url=https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkw056 | issn=0146-4760 | doi=10.1093/jat/bkw056}}</ref>


| Heavy || 12-15 mg+
===Dependence and abuse potential===
3-MeO-PCP [[Addiction potential::produces dependence with chronic use and has a high potential for abuse]]. In comparison to other [[dissociatives]], 3-MeO-PCP has been reported to be more likely to produce psychological dependence than other dissociatives. When dependence has developed, cravings and [[withdrawal effects]] may occur if one suddenly stops their usage. There are multiple online reports of users becoming seriously dependent on this substance.


|}
Tolerance to many of the effects of 3-MeO-PCP develops [[Time to full tolerance::with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). 3-MeO-PCP presents cross-tolerance with [[Cross-tolerance::all [[dissociative]]s]], meaning that after the consumption of 3-MeO-PCP, all [[dissociatives]] will have a reduced effect.


= Duration =
===Psychosis===
3-MeO-PCP has been reported to cause [[psychosis]], [[delusions]], and [[mania]] at a significantly higher rate than other [[dissociative]]s such as [[ketamine]], [[diphenidine]], or [[MXE]]. There are a large number of experience reports online which describe states of "psychotic delirium, amnesia, mania, and other serious consequences" after abusing 3-MeO-PCP.<ref name="three">The Big & Dandy 3-MeO-PCP Thread - Part 2 (Bluelight) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2</ref><ref name="two">The Big & Dandy 3-MeO-PCP Thread - Mad Manic Meo 3nity | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity</ref><ref name="one">The Big & Dandy 3-MeO-PCP Thread - Part 1 (Bluelight) | http://www.bluelight.org/vb/threads/454099-The-Big-amp-Dandy-3-MeO-PCP-Thread-%28Part-1%29</ref> In some cases, it has resulted in hospitalization and occasionally has taken up to a week or more to resolve.<ref name="six">{{cite journal | vauthors=((Bäckberg, M.)), ((Beck, O.)), ((Helander, A.)) | journal=Clinical Toxicology (Philadelphia, Pa.) | title=Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project | volume=53 | issue=9 | pages=856–864 | date= November 2015 | issn=1556-9519 | doi=10.3109/15563650.2015.1079325}}</ref><ref>The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 18 | 10-08-2014 09:10  | Post #448 by Sekio (Administrator) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12523821&viewfull=1#post12523821</ref><ref>The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 20 | 30-08-2014 14:08 | Post #481 by Chocodoobie | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12559322&viewfull=1#post12559322</ref><ref>The Big & Dandy 3-MeO-PCP Thread - Part 3 | Page 1 |  23-06-2015 11:53 | Post #5 by Confield | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity?p=13108675&viewfull=1#post13108675</ref><ref>{{Citation | title=3-MeO-PCP - Erowid Exp - “So Strong I’m Shocked” | url=https://www.erowid.org/experiences/exp.php?ID=103972}}</ref>


{| class="wikitable"
*Users should avoid taking 3-MeO-PCP for multiple days in a row or becoming dependent on it as this seems to be the main risk factor in the observed incidences of severe adverse effects.
*The recommended dosage range should not be exceeded as high doses can trigger these effects as well.
*Users should start with extremely low doses and work their way up as slowly as possible. [[Volumetric liquid dosing|Volumetric liquid dosing]] should preferably be used due to the drug's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg.
*[[Compulsive redosing]] before one has fully sobered up is not recommended and can result in too high of a dose.


|+ Oral
Due to the risk of psychosis, it is not recommended to combine this substance with other substances, especially [[stimulant]]s, [[psychedelic]]s, or other [[dissociative]]s like [[MXE]]. [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.


|-
It is strongly advised to use [[responsible drug use|harm reduction practices]] when using this substance.


| Onset || 20-40 minutes
===Urinary tract effects===
In terms of its long-term health effects when used repeatedly and excessively for extended periods of time, 3-MeO-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within [[ketamine]], but to a lesser extent. This is possibly because 3-MeO-PCP is far more potent than ketamine so significantly less of drug needs to be consumed.  Increased urinary tract effects will compound with usage of other drugs like amphetamine even if the drugs are not simultaneously used.{{Citation needed}}  Symptoms of ketamine-induced cystitis can become extremely serious and can be described as:


|-
*'''Urinary frequency''' - Urinary frequency is the need to empty the bladder every few minutes.
*'''Urinary urgency''' - This can be described as a sudden, compelling need to urinate.
*'''Urinary pressure''' - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
*'''Pelvic and bladder pain''' - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
*'''Hematuria''' - Hematuria is visible blood in the urine.
*'''Incontinence''' - This is the leakage of urine.


| Total || 3-5 hours +/- 60 minutes, dependent on dose.
These effects can be mitigated by refraining from using 3-MeO-PCP regularly (on a daily or weekly basis) and manually limiting one's usage of the substance.


|-
===Dangerous interactions===
{{DangerousInteractions/Intro}}


| After-effects || 2-48 hours
{{DangerousInteractions/Dissos}}
*[[MDMA]]: 3-MeO-PCP acts as a mild serotonin releasing agent and could interact negatively with the serotonin release of MDMA


|}
==Legal status==


{| class="wikitable"
*'''Austria:''' 3-MeO-PCP is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).{{citation needed}}
*'''Brazil:''' As of May 17, 2018, 3-MeO-PCP has been added to Portaria SVS/MS nº 344. Possession, distribution and use of this substance is now considered illegal.<ref>List of controlled substances: Portaria SVS/MS nº 344 (Portuguese) | http://portal.anvisa.gov.br/lista-de-substancias-sujeitas-a-controle-especial</ref>
*'''Germany:''' On November 21, 2015, 3-MeO-PCP was added to "Anlage II" of the controlled substance act ("BtMG"), making it illegal to produce, sell or possess.<ref>{{Citation | year=2015 | title=30. BtMÄndVO in Kraft getreten: 6 neue Stoffe wurden ins BtMG aufgenommen | url=https://community.beck.de/2015/11/23/30-btm-ndvo-in-kraft-getreten-6-neue-stoffe-wurden-ins-btmg-aufgenommen-0}}</ref>
*'''Denmark:''' As of August 25th, 2015, all MeO-PCP isomers (including 3-MeO-PCP) were added to the list of illegal substances in Denmark.<ref>{{Citation | title=Bekendtgørelse om euforiserende stoffer - ni nye stoffer tilføjet | url=https://laegemiddelstyrelsen.dk/da/nyheder/2015/bekendtgoerelse-om-euforiserende-stoffer-ni-nye-stoffer-tilfoejet/}}</ref>
*'''Sweden:''' Sweden's public health agency suggested classifying 3-MeO-PCP as a hazardous substance on November 10, 2014.<ref>Cannabinoider föreslås bli klassade som hälsofarlig vara | http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/</ref>
*'''Switzerland:''' 3-MeO-PCP is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''Turkey:''' 3-MeO-PCP is a classed as drug and is illegal to possess, produce, supply, or import.<ref name="Bakanlar Kurulu Kararı - Karar Sayısı : 2013/5742">{{Citation | title=Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü | url=https://resmigazete.gov.tr/eskiler/2014/01/20140125-3.htm}}</ref> <ref name="List of illegal substances for law"> https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf</ref>
*'''United Kingdom:''' 3-MeO-PCP is a class B drug in the UK and is illegal to possess, produce, supply, or import. As a derivative of 1-Phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group, further substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.<ref>{{Citation | title=The Misuse of Drugs Act 1971 (Amendment) Order 2013 | url=https://www.legislation.gov.uk/uksi/2013/239/introduction/made}}</ref>
*'''United States:''' 3-MeO-PCP is not a controlled substance in the United States but possession or distribution of 3-MeO-PCP for human use could potentially be prosecuted under the Federal Analogue Act due to its structural and pharmacological similarities to PCP.
*'''Czech Republic''': 3-MeO-PCP is a Schedule I controlled substance.<ref>{{Citation | vauthors=(([email protected], A. C.-)) | title=463/2013 Sb. Nařízení vlády o seznamech návykových látek | url=https://www.zakonyprolidi.cz/cs/2013-463}}</ref>
*'''The Netherlands''': 3-MeO-PCP is a Schedule I controlled substance.<ref>{{Citation| title=Opiumwet, Lijst I, (Dutch) | year=2023 | url=https://wetten.overheid.nl/BWBR0001941/2023-09-12#BijlageI}}</ref>
*'''Italy:''' 3-MeO-PCP is a Schedule I controlled substance.<ref>https://www.gazzettaufficiale.it/atto/vediMenuHTML?atto.dataPubblicazioneGazzetta=2021-10-18&atto.codiceRedazionale=21A06118&tipoSerie=serie_generale&tipoVigenza=originario</ref>


|+ Insufflated
==See also==


|-
*[[Responsible use]]
**[[Volumetric dosing]]
*[[Research chemical]]
*[[Dissociative]]
*[[Arylcyclohexylamine]]
*[[4-MeO-PCP]]
*[[PCP]]


| Onset || 10-30 minutes
==External links==


|-
*[https://en.wikipedia.org/wiki/3-MeO-PCP 3-MeO-PCP (Wikipedia)]
*[https://erowid.org/chemicals/3-meo-pcp/ 3-MeO-PCP (Erowid Vault)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=11015 3-MeO-PCP (Isomer Design)]


| Total || 2-4 hours +/- ~30 minutes, dependent on dose.
===Discussion and Media===


|-
*[http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2 The Big & Dandy 3-MeO-PCP Thread (Bluelight)]
*[https://web.archive.org/web/20170111011440*/https://www.vice.com/en_us/article/interview-with-ketamine-chemist-704-v18n2 Interview with a Ketamine Chemist (VICE)]


| After-effects || 2-48 hours
==Literature==


|}
*Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620


== Effects ==
==References==
 
{{reflist|2}}
=== Positive ===
 
* Increase in energy / stimulation
 
* Euphoria
 
* Pleasant mental and/or body high
 
* Music appreciation
 
* Disconnected thoughts
 
* Sense of calm
 
* Increased sociability, loss of inhibitions
 
* Closed and open-eye visuals
 
* Shifts in perception of reality
 
=== Neutral ===
 
* Increased heart rate (lower doses)
 
* Altered time perception
 
* Disrupted speech patterns
 
* Analgesia (decreased pain awareness) and numbness
 
* Distorted sensory perceptions, hallucinations
 
* Unusual and unpredictable behavior
 
* Mild to moderate dissociation
 
* Confusion, disorientation
 
=== Negative ===
 
* Disturbing hallucinations and/or delusions
 
* Anxiety, paranoia
 
* Severe dissociation, depersonalization
 
* Ataxia (loss of motor coordination)
 
* Psychotic episodes
 
* Nausea, vomiting
 
* Temporary amnesia
 
* Severe distortion or loss of auditory/visual perception
 
== Harm Reduction ==
 
* 3-Meo-PCP is a very powerful NMDA antagonist (doses are on par with [[PCP]]), and as such it has the potential to be very confusing.
* 3-MeO-PCP is considered to be a 'research-chemical', simply meaning that there is little to no clinical data on long-term effects.
* 3-MeO-PCP, as with all arylcyclohexylamine class dissociative compounds may cause neurotoxicity when used frequently or in high dose.
* 3-MeO-PCP acts as a mild Serotonin Reuptake Inhibitor and as such may risk adverse effects as a result of synergy when used with certain serotogenic drugs or medications. See [http://wiki.tripsit.me/wiki/3-MeO-PCP#Interactions Interactions].
* It is difficult to measure 3-MeO-PCP accurately with a scale because it is active in the 1-10 mg range. See [http://wiki.tripsit.me/wiki/3-MeO-PCP#Dosage the dosage section] for more information.
* 3-MeO-PCP has a steep dose-response-curve and an onset ranging from approximately 20-40 minutes. It is inadvisable to redose, especially within the first hour.
 
For more information see [http://wiki.tripsit.me/wiki/Dissociatives#Harm_Reduction Dissociative Harm-Reduction].
 
=== Interactions ===
 
Check out our [[Drug Combinations]] page and chart for interactions and combinations of common drugs.
PCP and 3-MeO-PCP have similar profiles and as such its safe to assume the PCP combination-chart data also applies to 3-MeO-PCP.
 
Specifically, do not mix 3-MeO-PCP with alcohol or benzodiazepines. 3-MeO-PCP will also likely produce synergistic effects if used in conjunction with certain serotogenic medications or drugs.
 
== Chemistry and Pharmacology ==
 
3-MeO-PCP binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. It is also a Serotonin Reuptake Inhibitor (SRI).
 
3-MeO-PCP hydrochloride is a white crystalline solid with a melting point of 204-205°C.
 
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptor.
 
== Legal status ==
 
UK: Class B, as are all arylcyclohexamines.
 
US: Covered by the analogue act if sold for human consumption.
 
== Links ==
 
[https://en.wikipedia.org/wiki/3-MeO-PCP Wikipedia]
 
[http://www.vice.com/read/interview-with-ketamine-chemist-704-v18n2 Interview with a Ketamine Chemist]
 
[http://onlinelibrary.wiley.com/doi/10.1002/dta.1620/abstract From MXE to PCP]
 
[[Category:Drugs]]


[[Category:Psychoactive substance]]
[[Category:Arylcyclohexylamine]]
[[Category:Piperidine]]
[[Category:Dissociative]]
[[Category:Dissociative]]
[[Category:Research chemical]]


[[category:Research Chemical]]
{{#set:Featured=true}}

Revision as of 00:04, 3 May 2025

File:Ambulance2.png

3-MeO-PCP may be more likely to cause mania, delusions, and psychosis than other dissociatives.[1][2][3]

It is strongly discouraged to take this substance in high dosages, for multiple days in a row, or in combination with other substances that increase the risk of psychosis. Please see this section for more details.

Not to be confused with 4-MeO-PCP.
Summary sheet: 3-MeO-PCP
{{#arraydefine: InhaledDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: InhaledDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: SmokedDosage | Threshold;Smoked threshold dose::2Smoked dose units::mg, Light;Smoked min light dose::5 - Smoked max light dose::10 mg, Common;Smoked min common dose::10 - Smoked max common dose::20 mg, Strong;Smoked min strong dose::20 - Smoked max strong dose::25 mg, Heavy;Smoked heavy dose::25 mg + Heavy doses may result in psychosis and mania.[4] }} {{#arraydefine: SmokedDuration | Total;Smoked min total time::45 - Smoked max total time::120Smoked total time units::minutes, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: OralDosage | Threshold;Oral threshold dose::2Oral dose units::mg, Light;Oral min light dose::4 - Oral max light dose::8 mg, Common;Oral min common dose::8 - Oral max common dose::15 mg, Strong;Oral min strong dose::15 - Oral max strong dose::25 mg, Heavy;Oral heavy dose::25 mg + Heavy doses may result in psychosis and mania.[4] }} {{#arraydefine: OralDuration | Total;Oral min total time::4 - Oral max total time::8Oral total time units::hours, Onset;Oral min onset time::30 - Oral max onset time::90Oral onset time units::minutes, Come up;Oral min comeup time::45 - Oral max comeup time::120Oral comeup time units::minutes, Peak;Oral min peak time::2 - Oral max peak time::3Oral peak time units::hours, Offset;Oral min offset time::1 - Oral max offset time::2Oral offset time units::hours, After effects;Oral min afterglow time::4 - Oral max afterglow time::48Oral afterglow time units::hours }} {{#arraydefine: SublingualDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: SublingualDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: BuccalDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: BuccalDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: InsufflatedDosage | Threshold;Insufflated threshold dose::1Insufflated dose units::mg, Light;Insufflated min light dose::2 - Insufflated max light dose::5 mg, Common;Insufflated min common dose::5 - Insufflated max common dose::10 mg, Strong;Insufflated min strong dose::10 - Insufflated max strong dose::15 mg, Heavy;15 mg + Heavy doses may result in psychosis and mania.[4] }} {{#arraydefine: InsufflatedDuration | Total;Insufflated min total time::3 - Insufflated max total time::5Insufflated total time units::hours, Onset;Insufflated min onset time::5 - Insufflated max onset time::30Insufflated onset time units::minutes, Come up;Insufflated min comeup time::45 - Insufflated max comeup time::90Insufflated comeup time units::minutes, Peak;Insufflated min peak time::1.5 - Insufflated max peak time::2Insufflated peak time units::hours, Offset;Insufflated min offset time::45 - Insufflated max offset time::60Insufflated offset time units::minutes, After effects;Insufflated min afterglow time::4 - Insufflated max afterglow time::48Insufflated afterglow time units::hours }} {{#arraydefine: RectalDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: RectalDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: TransdermalDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: TransdermalDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: SubcutaneousDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: SubcutaneousDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: IntramuscularDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: IntramuscularDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: IntravenousDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: IntravenousDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: uncertaininteractions | {{#ask:3-MeO-PCP |?UncertainInteraction |headers=hide |format=list |mainlabel=- |link=none }} }} {{#arraydefine: unsafeinteractions | {{#ask:3-MeO-PCP |?UnsafeInteraction |headers=hide |format=list |mainlabel=- |link=none }} }} {{#arraydefine: dangerousinteractions | {{#ask:3-MeO-PCP |?DangerousInteraction |headers=hide |format=list |mainlabel=- |link=none }} }} {{#arrayprint:uncertaininteractions||@@@@| }} {{#arrayprint:unsafeinteractions||@@@@| }} {{#arrayprint:dangerousinteractions||@@@@| }}
3-MeO-PCP
File:3-MeO-PCP.svg
Chemical Nomenclature
Common names common name::3-MeO-PCP, common name::3-MeO
Substitutive name 3-Methoxyphencyclidine
Systematic name 1-[1-(3-Methoxyphenyl)cyclohexyl]-piperidine
Class Membership
Psychoactive class psychoactive class::Dissociative
Chemical class chemical class::Arylcyclohexylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.


{{#arrayunique: SmokedDosage}} {{#loop: i | 0 | {{#arraysize: SmokedDosage}} | {{#arraydefine: val | {{#arrayindex: SmokedDosage | {{#var: i}} }} | ; }} }} {{#arrayunique: SmokedDuration}} {{#loop: i | 0 | {{#arraysize: SmokedDuration}} | {{#arraydefine: val | {{#arrayindex: SmokedDuration | {{#var: i}} }} | ; }} }}
⇣ Smoked
Dosage
[[Dosage_classification#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }}
Duration
[[Duration#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }}
{{#arrayunique: OralDosage}} {{#loop: i | 0 | {{#arraysize: OralDosage}} | {{#arraydefine: val | {{#arrayindex: OralDosage | {{#var: i}} }} | ; }} }} {{#arrayunique: OralDuration}} {{#loop: i | 0 | {{#arraysize: OralDuration}} | {{#arraydefine: val | {{#arrayindex: OralDuration | {{#var: i}} }} | ; }} }}
⇣ Oral
Dosage
[[Dosage_classification#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }}
Duration
[[Duration#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }}



{{#arrayunique: InsufflatedDosage}} {{#loop: i | 0 | {{#arraysize: InsufflatedDosage}} | {{#arraydefine: val | {{#arrayindex: InsufflatedDosage | {{#var: i}} }} | ; }} }} {{#arrayunique: InsufflatedDuration}} {{#loop: i | 0 | {{#arraysize: InsufflatedDuration}} | {{#arraydefine: val | {{#arrayindex: InsufflatedDuration | {{#var: i}} }} | ; }} }}
⇣ Insufflated
Dosage
[[Dosage_classification#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }}
Duration
[[Duration#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }}






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
@@@@
@@@@
@@@@


3-Methoxyphencyclidine (also known as 3-MeO-PCP) is a lesser-known novel Psychoactive class::dissociative substance of the Chemical class::arylcyclohexylamine class. 3-MeO-PCP is a derivative of phencyclidine (PCP) and is chemically related to substances like methoxetamine and 3-MeO-PCE. It produces its effects by blocking NMDA receptors in the brain.

3-MeO-PCP was first synthesized in 1979 in an investigation of phencyclidine (PCP) derivatives. However, its activity in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle reported qualitative similarities to PCP along with comparable potency.[5] In 2009, it began to be discussed on online forums such as bluelight.ru and was made available for sale on the research chemicals market.[5]

Like other arylcyclohexylamines, 3-MeO-PCP induces a state referred to as "dissociative anesthesia", although the extent to which this occurs is reported to be highly dose-dependent and variable in its effects. It is commonly taken orally and nasally, although it may also be smoked and injected. It has been noted for its subtle come up and tendency to produce delusions of sobriety, which can lead to compulsive redosing.

Very little data exists for the pharmacology, metabolism, and toxicity of 3-MeO-PCP. Due to its potent hallucinogenic effects and lack of research, it is strongly advised to use use harm reduction practices if using this substance.

Chemistry

3-Methoxyphencyclidine, or 3-MeO-PCP, is a synthetic dissociative of the arylcyclohexylamine class. 3-MeO-PCP contains cyclohexane, a six-member saturated ring, bonded to two additional rings at R1. One of these rings is a piperidine ring, a nitrogenous six member ring, bonded at its nitrogen group. The other ring is an aromatic phenyl ring, substituted at R3 with a methoxy group.

3-MeO-PCP is a PCP derivative and structurally analogous to 4-MeO-PCP.

Pharmacology

Further information: NMDA receptor antagonist

3-MeO-PCP acts as an NMDA receptor antagonist. A specific subtype of glutamate receptor, NMDA (N-Methyl-D-Aspartate), modulates the transmission of electrical signals between neurons in the brain and spinal cord; for the signals to pass, the receptor must be open.

Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually the equivalent of a "k-hole".

3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 42 nM for the sigma-1 receptor, 216 nM for the serotonin transporter (SERT), and 2960 nM with H1 receptor [6] [7] It binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP.[8] Like its sister compound PCP and unlike ketamine, 3-MeO-PCP shows a high affinity for inhibiting the relatively unstudied PCP2 glutamate receptor.[citation needed]

Although 3-MeO-PCP was once claimed to possess opioid or dopaminergic activity,[9] this supposition is contradicted by data showing 3-MeO-PCP to be a potent and selective ligand for the NMDA receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter.[10] 3-MeO-PCP was preceded by the less potent dissociative 4-MeO-PCP and first became available as a research chemical in 2011.[5]

Subjective effects

3-MeO-PCP is commonly described as being more stimulating and less immobilizing than other dissociatives such as ketamine or MXE.

At lower doses, it can induce sensory enhancements such as color enhancement, acuity enhancement, tactile enhancement, auditory enhancement and bodily control enhancement. At medium to high doses it presents sensory suppressions such as tactile suppression, motor control loss, auditory suppression and acuity suppression.

Based on a large amount of experience reports, it appears to be considerably more likely to induce mania, delusions, and psychosis than other dissociatives (possibly due to its unusually high potency, compulsivity and erratic dose response).

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.


{{ 

 #fornumargs: number
 | column
 |

{{#var: column}} }}

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include: {{#ask: |format=ul|Columns=1}} Additional experience reports can be found here:

Toxicity and harm potential

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens

The toxicity and long-term health effects of recreational 3-MeO-PCP use has not been studied in any scientific context and the exact Toxicity::toxic dosage is unknown. This is because 3-MeO-PCP has very short history of human usage.

There is one death involving this substance recorded in the medical literature. In this case, the individual's cause of death was determined to be from a combination of 3-MeO-PCP, amphetamine, and diphenhydramine.[11]

Dependence and abuse potential

3-MeO-PCP Addiction potential::produces dependence with chronic use and has a high potential for abuse. In comparison to other dissociatives, 3-MeO-PCP has been reported to be more likely to produce psychological dependence than other dissociatives. When dependence has developed, cravings and withdrawal effects may occur if one suddenly stops their usage. There are multiple online reports of users becoming seriously dependent on this substance.

Tolerance to many of the effects of 3-MeO-PCP develops Time to full tolerance::with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about Time to half tolerance::3 - 7 days for the tolerance to be reduced to half and Time to zero tolerance::1 - 2 weeks to be back at baseline (in the absence of further consumption). 3-MeO-PCP presents cross-tolerance with [[Cross-tolerance::all dissociatives]], meaning that after the consumption of 3-MeO-PCP, all dissociatives will have a reduced effect.

Psychosis

3-MeO-PCP has been reported to cause psychosis, delusions, and mania at a significantly higher rate than other dissociatives such as ketamine, diphenidine, or MXE. There are a large number of experience reports online which describe states of "psychotic delirium, amnesia, mania, and other serious consequences" after abusing 3-MeO-PCP.[12][13][14] In some cases, it has resulted in hospitalization and occasionally has taken up to a week or more to resolve.[15][16][17][18][19]

  • Users should avoid taking 3-MeO-PCP for multiple days in a row or becoming dependent on it as this seems to be the main risk factor in the observed incidences of severe adverse effects.
  • The recommended dosage range should not be exceeded as high doses can trigger these effects as well.
  • Users should start with extremely low doses and work their way up as slowly as possible. Volumetric liquid dosing should preferably be used due to the drug's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg.
  • Compulsive redosing before one has fully sobered up is not recommended and can result in too high of a dose.

Due to the risk of psychosis, it is not recommended to combine this substance with other substances, especially stimulants, psychedelics, or other dissociatives like MXE. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly advised to use harm reduction practices when using this substance.

Urinary tract effects

In terms of its long-term health effects when used repeatedly and excessively for extended periods of time, 3-MeO-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within ketamine, but to a lesser extent. This is possibly because 3-MeO-PCP is far more potent than ketamine so significantly less of drug needs to be consumed. Increased urinary tract effects will compound with usage of other drugs like amphetamine even if the drugs are not simultaneously used.[citation needed] Symptoms of ketamine-induced cystitis can become extremely serious and can be described as:

  • Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
  • Urinary urgency - This can be described as a sudden, compelling need to urinate.
  • Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
  • Pelvic and bladder pain - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
  • Hematuria - Hematuria is visible blood in the urine.
  • Incontinence - This is the leakage of urine.

These effects can be mitigated by refraining from using 3-MeO-PCP regularly (on a daily or weekly basis) and manually limiting one's usage of the substance.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • Stimulants - Both stimulants and dissociatives carry the risk of adverse psychological reactions like anxiety, mania, delusions and psychosis and these risks are exacerbated when the two substances are combined.
  • Depressants - Because both depress the respiratory system, this combination can result in an increased risk of suddenly falling unconscious, vomiting and choking to death from the resulting suffocation. If nausea or vomiting occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
  • MDMA: 3-MeO-PCP acts as a mild serotonin releasing agent and could interact negatively with the serotonin release of MDMA

Legal status

  • Austria: 3-MeO-PCP is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).[citation needed]
  • Brazil: As of May 17, 2018, 3-MeO-PCP has been added to Portaria SVS/MS nº 344. Possession, distribution and use of this substance is now considered illegal.[20]
  • Germany: On November 21, 2015, 3-MeO-PCP was added to "Anlage II" of the controlled substance act ("BtMG"), making it illegal to produce, sell or possess.[21]
  • Denmark: As of August 25th, 2015, all MeO-PCP isomers (including 3-MeO-PCP) were added to the list of illegal substances in Denmark.[22]
  • Sweden: Sweden's public health agency suggested classifying 3-MeO-PCP as a hazardous substance on November 10, 2014.[23]
  • Switzerland: 3-MeO-PCP is a controlled substance specifically named under Verzeichnis E.[24]
  • Turkey: 3-MeO-PCP is a classed as drug and is illegal to possess, produce, supply, or import.[25] [26]
  • United Kingdom: 3-MeO-PCP is a class B drug in the UK and is illegal to possess, produce, supply, or import. As a derivative of 1-Phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group, further substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.[27]
  • United States: 3-MeO-PCP is not a controlled substance in the United States but possession or distribution of 3-MeO-PCP for human use could potentially be prosecuted under the Federal Analogue Act due to its structural and pharmacological similarities to PCP.
  • Czech Republic: 3-MeO-PCP is a Schedule I controlled substance.[28]
  • The Netherlands: 3-MeO-PCP is a Schedule I controlled substance.[29]
  • Italy: 3-MeO-PCP is a Schedule I controlled substance.[30]

See also

External links

Discussion and Media

Literature

  • Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620

References

  1. ↑ The Big & Dandy 3-MeO-PCP Thread - Part 2 (Bluelight) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2
  2. ↑ The Big & Dandy 3-MeO-PCP Thread - Mad Manic Meo 3nity | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity
  3. ↑ The Big & Dandy 3-MeO-PCP Thread - Part 1 (Bluelight) | http://www.bluelight.org/vb/threads/454099-The-Big-amp-Dandy-3-MeO-PCP-Thread-%28Part-1%29
  4. ↑ 4.0 4.1 4.2 3-MeO-PCP Psychosis (PsychonautWiki) | https://psychonautwiki.org/wiki/3-MeO-PCP#Toxicity_and_harm_potential
  5. ↑ 5.0 5.1 5.2 Morris, H., Wallach, J. (July 2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs: PCP to MXE". Drug Testing and Analysis. 6 (7–8): 614–632. doi:10.1002/dta.1620. ISSN 1942-7603. 
  6. ↑ http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984
  7. ↑ Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012 
  8. ↑ http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984
  9. ↑ Morris, H. (2011), Interview with a Ketamine Chemist 
  10. ↑ Roth, B. L., Gibbons, S., Arunotayanun, W., Huang, X.-P., Setola, V., Treble, R., Iversen, L. (19 March 2013). "The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor". PLOS ONE. 8 (3): e59334. doi:10.1371/journal.pone.0059334. ISSN 1932-6203. 
  11. ↑ Bakota, E., Arndt, C., Romoser, A. A., Wilson, S. K. (September 2016). "Fatal Intoxication Involving 3-MeO-PCP: A Case Report and Validated Method". Journal of Analytical Toxicology. 40 (7): 504–510. doi:10.1093/jat/bkw056. ISSN 0146-4760. 
  12. ↑ The Big & Dandy 3-MeO-PCP Thread - Part 2 (Bluelight) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2
  13. ↑ The Big & Dandy 3-MeO-PCP Thread - Mad Manic Meo 3nity | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity
  14. ↑ The Big & Dandy 3-MeO-PCP Thread - Part 1 (Bluelight) | http://www.bluelight.org/vb/threads/454099-The-Big-amp-Dandy-3-MeO-PCP-Thread-%28Part-1%29
  15. ↑ Bäckberg, M., Beck, O., Helander, A. (November 2015). "Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project". Clinical Toxicology (Philadelphia, Pa.). 53 (9): 856–864. doi:10.3109/15563650.2015.1079325. ISSN 1556-9519. 
  16. ↑ The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 18 | 10-08-2014 09:10 | Post #448 by Sekio (Administrator) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12523821&viewfull=1#post12523821
  17. ↑ The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 20 | 30-08-2014 14:08 | Post #481 by Chocodoobie | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12559322&viewfull=1#post12559322
  18. ↑ The Big & Dandy 3-MeO-PCP Thread - Part 3 | Page 1 | 23-06-2015 11:53 | Post #5 by Confield | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity?p=13108675&viewfull=1#post13108675
  19. ↑ 3-MeO-PCP - Erowid Exp - “So Strong I’m Shocked” 
  20. ↑ List of controlled substances: Portaria SVS/MS nº 344 (Portuguese) | http://portal.anvisa.gov.br/lista-de-substancias-sujeitas-a-controle-especial
  21. ↑ 30. BtMÄndVO in Kraft getreten: 6 neue Stoffe wurden ins BtMG aufgenommen, 2015 
  22. ↑ Bekendtgørelse om euforiserende stoffer - ni nye stoffer tilføjet 
  23. ↑ Cannabinoider föreslås bli klassade som hälsofarlig vara | http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/
  24. ↑ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in Deutsch). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  25. ↑ Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü 
  26. ↑ https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf
  27. ↑ The Misuse of Drugs Act 1971 (Amendment) Order 2013 
  28. ↑ [email protected], A. C.-, 463/2013 Sb. Nařízení vlády o seznamech návykových látek 
  29. ↑ Opiumwet, Lijst I, (Dutch), 2023 
  30. ↑ https://www.gazzettaufficiale.it/atto/vediMenuHTML?atto.dataPubblicazioneGazzetta=2021-10-18&atto.codiceRedazionale=21A06118&tipoSerie=serie_generale&tipoVigenza=originario

{{#set:Featured=true}}

Retrieved from "https://www.drugwiki.net/wen/index.php?title=3-MeO-PCP&oldid=9010"